PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16740391-4	2006	IL-10-deficient NOD mice under such conditions were protected from spontaneous as well as cyclophosphamide-induced diabetes, but were susceptible to diabetes induced by adoptive transfer of splenocytes from spontaneously diabetic NOD mice.	Cyclophosphamide	90-106	interleukin 10	Mus musculus	0-5	
16522464-7	2006	There was also increased total and ovalbumin-specific serum IgE, increased IL-4 and IL-5 secretion by peritracheal lymph node cells, and reduced lung mRNA expression of IL-10 and TGF-beta in animals treated with cyclophosphamide.	Cyclophosphamide	212-228	interleukin 10	Mus musculus	169-174	
16522464-9	2006	Lung IL-10+CD4+ T cells and cytotoxic T lymphocyte-associated antigen 4+CD4+ T cells were reduced after allergen challenge in cyclophosphamide-treated mice.	Cyclophosphamide	126-142	interleukin 10	Mus musculus	5-10	
10896769-0	2000	IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse.	Cyclophosphamide	60-76	interleukin 10	Mus musculus	0-5	
12021086-9	2002	More importantly, the protective effect of gamma-GalCer in CY-accelerated T1D is abrogated by the in vivo blockade of IL-10 activity.	Cyclophosphamide	59-61	interleukin 10	Mus musculus	118-123	
10896769-5	2000	On the other hand, IL-10-deficient NOD mice developed accelerated disease following cyclophosphamide (CYP) injection.	Cyclophosphamide	84-100	interleukin 10	Mus musculus	19-24	
33840704-8	2021	RESULTS: CY/ZA significantly increased the relative expression levels of IL-6 and decreased those of IL-10 and IGF-1 when compared with those in VC.	Cyclophosphamide	9-11	interleukin 10	Mus musculus	101-106	
9797215-11	1998	Furthermore, acceleration of leukocyte recovery by IL-10 after cyclophosphamide-induced depression may also play an important role in this protection.	Cyclophosphamide	63-79	interleukin 10	Mus musculus	51-56	
9427742-4	1998	Spontaneous progression to diabetes, which can be accelerated by cyclophosphamide injection, is accompanied by a 10-fold increase in IFN-gamma and a 3-fold decrease in IL-10 and IL-4 production by the locally residing antigen-specific T cells.	Cyclophosphamide	65-81	interleukin 10	Mus musculus	168-173	
8830831-9	1996	Concomitantly, analysis of animals treated for 8 days after injection of cyclophosphamide, with IL-4 and IL-10, revealed a reduction of IL-12 mRNA in the pancreas.	Cyclophosphamide	73-89	interleukin 10	Mus musculus	105-110	
34667205-5	2021	However, intraperitoneal injection of cyclophosphamide suppressed IFN-gamma, TNF-alpha, and IL-10 expression.	Cyclophosphamide	38-54	interleukin 10	Mus musculus	92-97	
34667205-7	2021	However, LPS, ampicillin, cyclophosphamide all increased IIE and TNF-alpha to IL-10 expression (TIE) ratios.	Cyclophosphamide	26-42	interleukin 10	Mus musculus	78-83	
29954431-2	2018	The main objective of our research was to improve the effectiveness of dendritic cell (DC)-based immunotherapy or chemoimmunotherapy composed of cyclophosphamide (CY) and DCs by application of lentivectors encoding shRNA specific to IL-10 (shIL10 LVs) in murine colon carcinoma MC38 model.	Cyclophosphamide	145-161	interleukin 10	Mus musculus	233-238	
32104586-0	2020	Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis.	Cyclophosphamide	31-47	interleukin 10	Mus musculus	95-100	
29954431-2	2018	The main objective of our research was to improve the effectiveness of dendritic cell (DC)-based immunotherapy or chemoimmunotherapy composed of cyclophosphamide (CY) and DCs by application of lentivectors encoding shRNA specific to IL-10 (shIL10 LVs) in murine colon carcinoma MC38 model.	Cyclophosphamide	163-165	interleukin 10	Mus musculus	233-238	
28939510-6	2018	In addition, PSP treatment restored the levels of IL-2, TNF-alpha, IL-8 and IL-10 in the serum of the Cy-treated mice in a dose-dependent manner.	Cyclophosphamide	102-104	interleukin 10	Mus musculus	76-81	
27545090-7	2016	Furthermore, CAFs, stromal factors and immunosuppressive factors such as IL-10 and Tregs were also markedly decreased by the CY combination.	Cyclophosphamide	125-127	interleukin 10	Mus musculus	73-78	
29358974-5	2017	The level of the cytokine IL-10 in sera of cyclophosphamide-induced mice was decreased after pretreatments of polysaccharides.	Cyclophosphamide	43-59	interleukin 10	Mus musculus	26-31	
25454807-5	2015	The high tumour growth inhibition was observed in mice treated with CY+anti-IL-10+BMDC/TAg as well as CY+-anti-IL-10+BMDC/TAg+BMDC/IL-12.	Cyclophosphamide	68-71	interleukin 10	Mus musculus	76-81	
27498213-0	2016	Enhancement of fibroblast activation protein alpha-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.	Cyclophosphamide	99-115	interleukin 10	Mus musculus	135-140	
27498213-7	2016	However, heterologous vaccination in combination with a low-dose of cyclophosphamide (CY), which was reported to reduce IL-10 production and promote a shift from immunosuppression to immunopotentiation, resulted in enhanced effects in terms of numbers of effector T cells and tumor growth inhibition rates, compared to the CY alone or DNA alone group.	Cyclophosphamide	68-84	interleukin 10	Mus musculus	120-125	
27498213-7	2016	However, heterologous vaccination in combination with a low-dose of cyclophosphamide (CY), which was reported to reduce IL-10 production and promote a shift from immunosuppression to immunopotentiation, resulted in enhanced effects in terms of numbers of effector T cells and tumor growth inhibition rates, compared to the CY alone or DNA alone group.	Cyclophosphamide	86-88	interleukin 10	Mus musculus	120-125	
25454807-0	2015	Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.	Cyclophosphamide	61-77	interleukin 10	Mus musculus	25-30	
25454807-5	2015	The high tumour growth inhibition was observed in mice treated with CY+anti-IL-10+BMDC/TAg as well as CY+-anti-IL-10+BMDC/TAg+BMDC/IL-12.	Cyclophosphamide	102-105	interleukin 10	Mus musculus	111-116	
25454807-9	2015	The high cytotoxic activity of spleen-derived NK cells and increased influx of these cells into tumours of mice treated with CY+anti-IL-10+BMDC/TAg indicate that mice from the group developed strong NK-dependent response.	Cyclophosphamide	125-128	interleukin 10	Mus musculus	133-138	
24080320-4	2013	ELISA experiments showed that COS treatment enhanced production of the cytokines IL-2, IL-12, and IFN-gamma but decreased production of IL-10 in sera of Cy-treated mice.	Cyclophosphamide	153-155	interleukin 10	Mus musculus	136-141